EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
Published: Aug 07, 2009
HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.
About EGEN, Inc.
EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.